Morality predictors in acute exacerbation of idiopathic pulmonary fibrosis

G. Dabar, M. Iskandar, B. Habr, Z. Aoun, M. Riachy, G. Khayat (Beirut, Lebanon)

Source: International Congress 2014 – ILDs 6
Session: ILDs 6
Session type: Thematic Poster Session
Number: 3789
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Abstract

Background: Acute Exacerbation (AE) of Idiopathic Pulmonary Fibrosis (IPF) is the sudden acceleration of disease process superimposed on a diseased lung affected by IPF. Our objective is to find predictors of mortality in AE of IPF in our population.Design: Medical records review for the world pulmonary fibrosis from 2000 through 2012, followed by a manual review of the identified records that fit the criteria of AE of IPF. 71 patients with fibrosis were found. AE was identified in 30-discharge summary, 24 were analyzed and 6 medical records were missing.Setting: The studied patients were treated at the Hotel Dieu Hospital in Beirut by a group of pulmonologists without a predefined common protocol.Method: Data were collected from medical records and chest computerized tomography (CT) scans were reviewed.Statistical analysis: Pearson Chi-Square test was used to detect significant differences in patient's characteristics between survivors and non-survivors.Results: 18 exacerbation survived and 6 died, no difference was found in age, disease length, smoking, FVC, diffusion, infection 3 month prior to exacerbation. C-reactive protein (CRP) and Maximum oxygen use were significantly higher in the Non-survivors group while Procalcitonin or (+) sputum cultures were similar. CT scanner findings did not differ between the 2 groups. Patients who did not survive were more likely to have treatment limitation and stayed longer. A multivariable analysis included age, FVC, diffusion, CRP, maximal dose of steroids, and alveolitis, no correlation was found with mortality.Conclusion: In AE of IPF survivors and non-survivors had same characteristics, however higher CRP and resource utilization were noticed in non-survivors.


Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Dabar, M. Iskandar, B. Habr, Z. Aoun, M. Riachy, G. Khayat (Beirut, Lebanon). Morality predictors in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2014; 44: Suppl. 58, 3789

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014


Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014



Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014


Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 2
Year: 2014

Recent improvement of survival of acute exacerbation in idiopathic interstitial pneumonias: 10 years experience
Source: International Congress 2014 – ILDs 2
Year: 2014

Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014


Airway centered interstitial fibrosis – An under-recognized type of idiopathic interstitial pneumonia
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014


Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment
Source: International Congress 2014 – ILDs 5
Year: 2014


Comparison of physiological impairment in ILD patients with and without diagnostic IPF features
Source: International Congress 2014 – ILDs 4
Year: 2014


Evolution of an interstitial lung disease MDT: 5.5 years of data
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014


Comparison between patients with idiopathic pulmonary fibrosis and patients with pulmonary involvement of the usual interstitial pneumonia pattern that preceded the onset of rheumatoid arthritis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014

Does CRP predicts severity of hospitalized patients with diffuse interstitial lung disease?
Source: International Congress 2014 – ILDs 5
Year: 2014

Aetiological panorama in the diagnosis of interstitial lung diseases
Source: International Congress 2014 – ILDs 5
Year: 2014


Pregnancy course in patients with interstitial lung diseases
Source: International Congress 2014 – ILDs 5
Year: 2014


Prognostic significance of selected biomarkers in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease
Source: International Congress 2014 – Sarcoidosis
Year: 2014


Does hypoxemia increases risks in hospitalized patients with diffuse interstitial lung disease?
Source: International Congress 2014 – ILDs 6
Year: 2014

Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort
Source: International Congress 2014 – ILDs 4
Year: 2014


A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2014 – IPF and surroundings
Year: 2014

Reduction in disease progression with nintedanib in the INPULSIS™ trials
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014


The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital
Source: International Congress 2014 – ILDs 4
Year: 2014